7 results about "Bioresorbable polymers" patented technology

The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

The present invention provides a method of preventing blood coagulation comprising administering to a subject in need thereof an effective amount of ginsenoside compound K (CK). The invention also provides an application of the ginsenoside compound K (CK) in preparation of a medicine for preventing blood coagulation. Further, the present invention provides a drug-eluting percutaneous coronary intervention therapy (PCI) comprising a vascular implant wherein a surface of the vascular implant is coated with a first layer comprising a ginsenoside compound K (CK) and a first bioresorbable polymer, wherein the first bioabsorbable polymer comprises poly-L-lactic acid (PLLA) and poly (L-lactide-co-epsilon-caprolactone) (PLCL) in a weight ratio of 60% to 80%: 20% to 40%.

The present technology relates to depot assemblies for the controlled, sustained release of a therapeutic agent. The assembly can include a depot having a therapeutic region comprising a therapeutic agent, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and / or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

Methods of repairing composite tissue injuries susceptible to adipocyte infiltration, by applying to the injury an electrospun polymer fiber scaffold comprising biocompatible and bioresorbable polymer fibers that are blended with an amount of a GSK-3 inhibitor that is effective to inhibit the infiltration of adipocytes into the scaffold and tissue. Polymer scaffolds blended with an amount of a GSK-3 inhibitor that is effective to inhibit the infiltration of adipocytes into the scaffold and tissue are also disclosed as are kits containing the scaffolds and stem cells for repairing tissue at the injury site.

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.